Related Experiment Videos
Insights
Maternal drug use during pregnancy is a concern for congenital heart disease (CHD) risk. However, evidence shows most heart defects are not caused by these medications.
Area of Science:
- Cardiology
- Teratology
- Epidemiology
Background:
- Congenital heart disease (CHD) is a significant component of major birth defects, affecting approximately 0.9% of infants.
- The etiology of most cardiac defects remains largely unknown.
- Maternal drug exposure during embryonic development is a suspected risk factor.
Purpose of the Study:
- To review and analyze epidemiologic evidence linking maternal drug use during pregnancy to the occurrence of congenital heart disease.
- To evaluate the role of specific pharmacologic agents in the development of fetal cardiac malformations.
Main Methods:
- Systematic review and analysis of epidemiologic studies.
- Examination of evidence regarding maternal use of ethanol, anticonvulsants, lithium, exogenous hormones, and doxylamine.
- Assessment of the contribution of these agents to the overall incidence of CHD.
Main Results:
- Evidence suggests that maternal use of ethanol, anticonvulsants, lithium, and exogenous female hormones may elevate the risk of CHD.
- An antiemetic containing doxylamine has been specifically implicated.
- The vast majority of congenital heart malformations cannot be attributed to these studied pharmacologic agents.
Conclusions:
- While certain maternal medications are associated with an increased risk of CHD, they are not the primary cause for most cases.
- Further research is needed to fully elucidate the complex etiology of congenital heart defects.
- This review underscores the importance of evaluating drug safety during pregnancy but contextualizes the overall contribution of pharmacologic agents to CHD incidence.
Abstract:
Congenital heart disease comprises one-third of all major birth defects. Prevalence estimates depend on the definition of the disease and the postnatal period when the disease is diagnosed. The studies with the longest follow-up estimate that 0.9% of infants are afflicted. The cause of these cardiac defects is largely unknown. The effect of embryonic exposure to maternal drugs during cardiogenesis has been widely studied, and the evidence suggests that maternal use of ethanol, anticonvulsants, lithium, and exogeneous female hormones may increase the risk of congenital heart disease. An antiemetic agent containing doxylamine has been implicated in the courts. This review offers an analysis of the epidemiologic evidence of the occurrence of congenital heart disease in relation to maternal drug use during pregnancy. The evidence indicates that the vast majority of heart malformations cannot be attributed to these pharmacologic agents.